These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 28666800

  • 61. Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Park J, Lim CS, Seo H, Park CA, Zhuo M, Kaang BK, Lee K.
    Mol Pain; 2015 May 17; 11():28. PubMed ID: 25981600
    [Abstract] [Full Text] [Related]

  • 62. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.
    Neurobiol Dis; 2012 Mar 17; 45(3):1051-67. PubMed ID: 22198503
    [Abstract] [Full Text] [Related]

  • 63. Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson's Disease.
    Wu P, Dong Y, Chen J, Guan T, Cao B, Zhang Y, Qi Y, Guan Z, Wang Y.
    Neurotox Res; 2022 Feb 17; 40(1):286-297. PubMed ID: 35043376
    [Abstract] [Full Text] [Related]

  • 64. The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease.
    Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, Hölscher C.
    Am J Alzheimers Dis Other Demen; 2020 Feb 17; 35():1533317520953041. PubMed ID: 32959677
    [Abstract] [Full Text] [Related]

  • 65. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.
    Parthsarathy V, Hölscher C.
    Eur J Pharmacol; 2013 Jan 30; 700(1-3):42-50. PubMed ID: 23276669
    [Abstract] [Full Text] [Related]

  • 66. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
    Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, Valencia-Torres L, Aviello G, Hodson DJ, Snider BM, Coskun T, Emmerson PJ, Luckman SM, D'Agostino G.
    Mol Metab; 2022 Jan 30; 55():101407. PubMed ID: 34844019
    [Abstract] [Full Text] [Related]

  • 67. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z, Xu S, Du N, Liu J, Huang Y, Han M.
    Neurosci Lett; 2016 Mar 11; 616():152-9. PubMed ID: 26827716
    [Abstract] [Full Text] [Related]

  • 68. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
    Xu G, Xiong Z, Yong Y, Wang Z, Ke Z, Xia Z, Hu Y.
    Neuroscience; 2010 Apr 28; 167(1):174-84. PubMed ID: 20123001
    [Abstract] [Full Text] [Related]

  • 69. [GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].
    Jiao JJ, Hölscher C, Li T, Dong XF, Qu XS, Cao Y, Wu MN, Wang ZJ, Qi JS.
    Sheng Li Xue Bao; 2017 Apr 25; 69(2):135-145. PubMed ID: 28435972
    [Abstract] [Full Text] [Related]

  • 70. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J, Carrillo-S C, García E, Ruiz-Mar G, Pérez-Tamayo R, Chavarría A.
    Toxicology; 2014 May 07; 319():38-43. PubMed ID: 24607817
    [Abstract] [Full Text] [Related]

  • 71. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
    West JA, Tsakmaki A, Ghosh SS, Parkes DG, Grønlund RV, Pedersen PJ, Maggs D, Rajagopalan H, Bewick GA.
    PLoS One; 2021 May 07; 16(3):e0249239. PubMed ID: 33788878
    [Abstract] [Full Text] [Related]

  • 72. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
    Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M, Hirano T.
    Peptides; 2014 Apr 07; 54():19-26. PubMed ID: 24418070
    [Abstract] [Full Text] [Related]

  • 73. Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.
    Lin TK, Lin KJ, Lin HY, Lin KL, Lan MY, Wang PW, Wang TJ, Wang FS, Tsai PC, Liou CW, Chuang JH.
    Front Mol Neurosci; 2021 Apr 07; 14():697440. PubMed ID: 34305527
    [Abstract] [Full Text] [Related]

  • 74. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO, Glotfelty EJ, Li Y, Greig NH.
    Pharmacol Res; 2022 Dec 07; 186():106550. PubMed ID: 36372278
    [Abstract] [Full Text] [Related]

  • 75. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y, Ji T, Lv J, Wang Z.
    Life Sci; 2020 Sep 15; 257():118025. PubMed ID: 32598933
    [Abstract] [Full Text] [Related]

  • 76. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.
    Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI.
    Inflammopharmacology; 2017 Jun 15; 25(3):369-382. PubMed ID: 28258522
    [Abstract] [Full Text] [Related]

  • 77. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-κB signaling pathway.
    Koo JH, Jang YC, Hwang DJ, Um HS, Lee NH, Jung JH, Cho JY.
    Neuroscience; 2017 Jul 25; 356():102-113. PubMed ID: 28527958
    [Abstract] [Full Text] [Related]

  • 78. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.
    Bossart M, Wagner M, Elvert R, Evers A, Hübschle T, Kloeckener T, Lorenz K, Moessinger C, Eriksson O, Velikyan I, Pierrou S, Johansson L, Dietert G, Dietz-Baum Y, Kissner T, Nowotny I, Einig C, Jan C, Rharbaoui F, Gassenhuber J, Prochnow HP, Agueusop I, Porksen N, Smith WB, Nitsche A, Konkar A.
    Cell Metab; 2022 Jan 04; 34(1):59-74.e10. PubMed ID: 34932984
    [Abstract] [Full Text] [Related]

  • 79. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
    Tasaki Y, Yamamoto J, Omura T, Sakaguchi T, Kimura N, Ohtaki K, Ono T, Suno M, Asari M, Ohkubo T, Noda T, Awaya T, Shimizu K, Matsubara K.
    Neurosci Lett; 2012 Jul 11; 521(1):15-9. PubMed ID: 22617635
    [Abstract] [Full Text] [Related]

  • 80. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
    Biju K, Zhou Q, Li G, Imam SZ, Roberts JL, Morgan WW, Clark RA, Li S.
    Mol Ther; 2010 Aug 11; 18(8):1536-44. PubMed ID: 20531393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.